Kodu・Aktsiate loetelu・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Avatud

SektorTervishoid

3.34 0.91

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.2800000000000002

Max

3.43

Põhinäitajad
By Trading Economics
Sissetulek	-2.4M -21M
Müük	-8.8M 1.4M
P/E Sektori keskmine	22.5 57.366
Aktsiakasum	-0.09
Kasumimarginaal	-1,457.405
Töötajad	69
EBITDA	-2.4M -20M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+285.54% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. nov 2026

Turustatistika
By TradingEconomics
Turukapital	27M 717M
Eelmine avamishind	2.43
Eelmine sulgemishind	3.34

Uudiste sentiment

By Acuity

50%

160 / 340 Pingereas Healthcare

CytomX Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. aug 2026, 19:56 UTC

CytomX Therapeutics is trading higher amid positive market conditions and lower crude oil prices, which have decreased treasury yields and boosted investor sentiment.

24. aug 2026, 19:26 UTC

CytomX Therapeutics is trading higher, reflecting gains since Friday's close. Earlier, shares peaked with a gain before pulling back to a modest advance.

21. aug 2026, 19:46 UTC

CytomX Therapeutics Inc. is gaining during Friday's session, despite earlier volatility. No specific company news was identified to explain today's price movement.

20. aug 2026, 21:01 UTC

CytomX Therapeutics Inc shares are higher in after-market hours, reflecting unusual trading activity. The stock is positioned around the midpoint of its one-month range.

19. aug 2026, 20:02 UTC

CytomX Therapeutics is trading higher during Wednesday's session, continuing a strong upward move since Tuesday's close amid notable volatility.

14. aug 2026, 19:36 UTC

Social Media

CytomX Therapeutics is higher as social media highlights its undervaluation, with a suggested price target of $6-7 ahead of year-end data releases.

13. aug 2026, 22:01 UTC

CytomX Therapeutics shares are higher in after-market trading, supported by broader market strength and a record closing high for the S&P 500.

12. aug 2026, 19:46 UTC

CytomX Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close, supported by positive sentiment from the recent inflation report.

11. aug 2026, 23:21 UTC

CytomX Therapeutics Inc. shares are higher in after-market trading, reaching 1.45% above Tuesday's close amid strong performance relative to its moving average.

10. aug 2026, 23:31 UTC

CytomX Therapeutics Inc shares are lower in after-market hours after earlier volatility. Broader market sentiment remains cautious amid geopolitical tensions in the Strait of Hormuz.

7. aug 2026, 19:16 UTC

Social Media

News

CytomX Therapeutics expands collaboration with Regeneron on immunotherapies and updates on Varseta-M program, boosting sentiment amid a rising Biotechnology sector.

6. aug 2026, 22:02 UTC

Social Media

News

CytomX Therapeutics shares declined in after-market hours following a significant revenue miss of $1.418 million against expectations of $12.308 million.

31. juuli 2026, 20:06 UTC

CytomX Therapeutics Inc shares declined sharply during Friday's session, reversing earlier gains and trading well below the 20-day moving average. No specific news was identified.

29. juuli 2026, 19:47 UTC

CytomX Therapeutics shares are lower as traders await the Federal Reserve's interest rate decision, contributing to mixed performance across major U.S. indices.

28. juuli 2026, 17:46 UTC

CytomX Therapeutics shares are lower today, reflecting a broader cautious tone across Asian markets. The stock remains near its one-month low.

27. juuli 2026, 23:26 UTC

CytomX Therapeutics shares are higher in after-market hours, though no specific news was identified. Broader positive sentiment in European indices may be influencing investors.

21. juuli 2026, 19:56 UTC

CytomX Therapeutics Inc shares are lower today, continuing a downward trend. The stock remains significantly below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

CytomX Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

285.54% tõus

12 kuu keskmine prognoos

Keskmine 12.8 USD 285.54%

Kõrge 16 USD

Madal 11 USD

Põhineb 5 Wall Streeti analüütiku instrumendi CytomX Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi CytomX Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

160 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.